Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Voyageur Pharmaceuticals ( (TSE:VM) ) just unveiled an update.
Voyageur Pharmaceuticals has launched its barium contrast product line in Canada and other markets adhering to Health Canada standards, following successful clinical studies. The company received positive feedback from a study conducted at Canada Diagnostic Centres, positioning its products on par with existing market offerings. With the initiation of phase II testing for FDA licensing and the development of the Frances Creek project, Voyageur aims to strengthen its market position and expand globally, highlighting its commitment to innovation and supply chain security.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. is a radiology contrast media company focused on vertical integration and secure supply chains. The company specializes in barium contrast media products, targeting diagnostic imaging centers and aiming to establish a strong presence in the contrast media market.
Average Trading Volume: 28,905
Technical Sentiment Signal: Sell
Current Market Cap: $17.42M
For an in-depth examination of VM stock, go to TipRanks’ Stock Analysis page.